Thrombosis News and Research RSS Feed - Thrombosis News and Research

Thrombosis is the formation or presence of a thrombus (blood clot) inside a blood vessel.
New data focuses on different approaches to improve diagnosis and treatment of HCC

New data focuses on different approaches to improve diagnosis and treatment of HCC

Epidemiological, genetic and clinical data presented today at the International Liver CongressTM 2014 are collectively focussed on different approaches designed to improve the diagnosis, staging and treatment of hepatocellular carcinoma (HCC). [More]
Pradaxa receives FDA approval for treatment and reduction of risk of recurrence of DVT and PE

Pradaxa receives FDA approval for treatment and reduction of risk of recurrence of DVT and PE

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. DVT and PE are collectively referred to as venous thromboembolism (VTE). [More]
Boston Scientific presents new data on cardiology-related clinical trials at ACC 2014

Boston Scientific presents new data on cardiology-related clinical trials at ACC 2014

Reinforcing its position as a global leader in bringing new therapies to patients with heart and cardiovascular disease, Boston Scientific Corporation (NYSE: BSX) reported favorable results in studies related to cardiac resynchronization therapy (CRT), platinum chromium stent platforms and transcatheter aortic valve replacement (TAVR). [More]
Scientists discover how MRP-14 gene generates dangerous clots that could trigger heart attack

Scientists discover how MRP-14 gene generates dangerous clots that could trigger heart attack

Right now, options are limited for preventing heart attacks. However, the day may come when treatments target the heart attack gene, myeloid related protein-14 (MRP-14, also known as S100A9) and defang its ability to produce heart attack-inducing blood clots, a process referred to as thrombosis. [More]
Heparin proves effective than bivalirudin in patients receiving percutaneous coronary intervention after heart attack

Heparin proves effective than bivalirudin in patients receiving percutaneous coronary intervention after heart attack

In a comparison of two blood-thinning medications, heparin was associated with significantly fewer major cardiovascular events at 28 days than bivalirudin in patients receiving primary percutaneous coronary intervention after a heart attack, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session. [More]
New report reveals potential breakthrough in pterygium treatment

New report reveals potential breakthrough in pterygium treatment

A new report reveals a potential breakthrough in the treatment of a common eye ailment known as pterygium (Surfer's eye) that impacts the vision, eye health, and cosmetic appearance of countless sufferers. [More]

rEVO Biologics commences ATryn Phase 3 clinical program for treatment of preeclampsia in pregnant women

rEVO Biologics Inc., a subsidiary of LFB SA, today announced the initiation of the Phase 3 clinical program for ATryn for the treatment of preeclampsia in pregnant women during the 24th to 28th week of pregnancy. [More]

Enrollment commences for Daiichi Sankyo's ENSURE-AF multinational phase 3 study in NVAF patients

Daiichi Sankyo Company, Limited today announced that it has started enrolling patients into the ENSURE-AF multinational phase 3 study, which will evaluate the efficacy and safety of its investigational oral, once-daily direct factor Xa-inhibitor edoxaban compared to enoxaparin/warfarin for the prevention of stroke and other blood clot complications in patients with non-valvular atrial fibrillation (NVAF) undergoing electrical cardioversion (low-energy shocks to trigger normal heart rhythm). [More]

SEATTLE II study confirms safety and efficacy of thrombolytic therapy for acute PE

EKOS Corporation, a BTG International group company, notes the presentation of the results of the SEATTLE II trial this afternoon at ACC.14, the 63rd Annual Scientific Session and Exposition of the American College of Cardiology in Washington, DC in the United States. [More]

New angiographic analysis examines impact of stent thrombosis in patients undergoing PCI

A new angiographic analysis of the CHAMPION PHOENIX trial examined the incidence and impact of stent thrombosis (ST) in patients undergoing percutaneous coronary intervention (PCI). Results of the study were released today and will be presented March 30 at the American College of Cardiology 63rd Annual Scientific Session. [More]
Biogen Idec's ALPROLIX receives FDA approval for hemophilia B treatment

Biogen Idec's ALPROLIX receives FDA approval for hemophilia B treatment

Today Biogen Idec announced that the U.S. Food and Drug Administration has approved ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], the first recombinant, DNA derived hemophilia B therapy with prolonged circulation in the body. [More]
Marriage linked to lower risk of cardiovascular disease

Marriage linked to lower risk of cardiovascular disease

Marriage is criticized for many things — justly and unjustly — but not heart disease, according to findings of a recent study conducted by researchers at NYU Langone Medical Center. [More]

Marital status affects risk of heart disease, survey shows

Analysis of surveys of more than 3.5 million American men and women, administered at some 20,000 health centers across the country - believed to be the largest analysis of its kind ever performed - found that married people, regardless of age, sex, or even cardiovascular risk factors, had significantly less chances of having any kind of cardiovascular disease than those who were single, divorced or widowed. [More]
New approach can improve patient outcomes, reduce complications in complex spine surgeries

New approach can improve patient outcomes, reduce complications in complex spine surgeries

A new team approach has improved safety-reducing rates of major complications by two thirds-for complex spinal reconstructive surgery for spinal deformity in adult Group Health patients at Virginia Mason Hospital & Seattle Medical Center. [More]

ISTH declares Oct.13 as World Thrombosis Day

Bringing together nations and local communities to tackle thrombosis, the quiet, underlying disorder that is the common mechanism of the world's three top cardiovascular killers – heart attack, stroke and venous thromboembolism (VTE) – the International Society on Thrombosis and Haemostasis (ISTH) today announced that October 13 will be designated World Thrombosis Day, with the inaugural event to be held this year. [More]
Protein known to promote cancer appears to give blood vessels strength and shape, researchers report

Protein known to promote cancer appears to give blood vessels strength and shape, researchers report

A protein known to promote cancer appears to give the blood vessels strength and shape, researchers report. When yes-associated protein, or YAP, is deleted from vascular smooth muscle cells during development, the protein makes thin-walled blood vessels that over-dilate in response to the usual pressure of blood flow, said Dr. Jiliang Zhou, vascular biologist at the Medical College of Georgia at Georgia Regents University. [More]

Renal mass biopsy rates increasing in kidney cancer

Rates of renal mass biopsy have been historically low in patients with kidney cancer, but are steadily rising, shows an analysis of Medicare data. [More]
Proteomics identifies possible RCC biomarkers

Proteomics identifies possible RCC biomarkers

Proteomic analysis has identified significant differences between the proteins expressed in renal cell carcinoma samples and in healthy renal tissue, UK researchers report. [More]

Cytoplasmic HIF-2α linked to poor prognosis in renal cell carcinoma

Cytoplasmic expression of hypoxia inducible factor-2α is associated with poor prognosis in patients with clear cell renal cell carcinoma, study findings indicate. [More]
Researchers discover certain proteins in osteoclasts that may be used to destroy cardiovascular calcification

Researchers discover certain proteins in osteoclasts that may be used to destroy cardiovascular calcification

​Cardiovascular calcification (deposits of minerals in heart valves and blood vessels) is a primary contributor to heart disease, the leading cause of death among both men and women in the United States according the Centers for Disease Control and Prevention (CDC). [More]